Skip to main content
SpringerLink
Log in

The Genetics of Adverse Drug Reactions

Promises and Problems

  • Protocol
Pharmacogenomics and Personalized Medicine

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

There is increasing pressure from patients, health care providers, regulatory authorities, and pharmaceutical companies and their shareholders to bring safer drugs to the market. Despite highly regulated preclinical screening and clinical monitoring, drugs do still make it onto the market that have potentially serious safety issues. The reasons why only a small minority of exposed patients experience these adverse drug reactions (ADRs) are uncertain, but there is increasing interest in the study of genetics as one of the potential susceptibility factors. The following chapter reviews the major advances in this area, discusses how genetics can be used in understanding and mitigating ADR risk, highlights the major challenges associated with performing research in this area, and looks at some of the potential solutions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar KB, Kevin Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15–19

    Article  PubMed  Google Scholar 

  2. Jefferys DB, Leakey D, Lewis JA, Payne S, Rawlins MD (1998) New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmcol 45: 151–156.

    Article  CAS  Google Scholar 

  3. http://www.fda.gov/bbs/topics/news/2004/NEW01122.html.

  4. http://money.cnn.com/2004/09/30/news/fortune500/merck/?cnn=yes.

  5. http://www.adrugrecall.com/news/baycol-bayer.html.

  6. http://en.wikipedia.org/wiki/TGN1412.

  7. Howard Rl, Avery AJ, Slavenburg S, Royal S, Pipe P, Lucassen P, Pirmohamed M (2006) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63:136–147

    Article  PubMed  Google Scholar 

  8. http://www.findarticles.com/p/articles/mi_m0ISW/is_2001_June/ai_75178713.

  9. Pirmohamed M, Park BK (2001) Genetic susceptibility to adverse drug reactions. TIPS 22:298–305.

    CAS  PubMed  Google Scholar 

  10. Rothenberg ML, Meropol NJ, Poplin EA (2001) Mortaility associated with irinotecan plus bolus flouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807.

    CAS  PubMed  Google Scholar 

  11. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189–1192.

    CAS  PubMed  Google Scholar 

  12. Fisher MB, VandenBranden M, Findlay K, Burchell B, Thummel KE, Hall SD, Wrighton SA (2000) Tissue distribution and interindividual variation in human UDP-glucuronosyltrans-ferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727–739

    Article  CAS  PubMed  Google Scholar 

  13. McLeod Hl, Watters JW (2004) Irinotecan pharmacogenetics: is it time to intervene. J Clin Oncol 22:1356–1359

    Article  PubMed  Google Scholar 

  14. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucurono-syltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–8.

    Article  CAS  PubMed  Google Scholar 

  15. Haga SB, Thummel KE, Burke W (2006) Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genom 16:847–854

    Article  CAS  Google Scholar 

  16. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT (2002) Association between presence of HLA-B *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727–732

    Article  CAS  PubMed  Google Scholar 

  17. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121–22.

    Article  CAS  PubMed  Google Scholar 

  18. Hughes DA, Javier V, Ward CC, Alfirevic A, Park KB, Pirmohamed M (2004) Cost-effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14:335–342

    Article  PubMed  Google Scholar 

  19. March R (2006) Challenges and opportunities of pharmacogenetics in drug development. Personalised Medicine 3:195–206

    Article  CAS  Google Scholar 

  20. Piquette RK (1999) Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 33:22–26

    Article  CAS  PubMed  Google Scholar 

  21. Paulussen ADC, Gilissen RAHJ, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJM, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J (2004) Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 82:182–188

    Article  CAS  PubMed  Google Scholar 

  22. Carr DF, Alfirevic A, Tugwood JD, Barratt BJ, Sherwood J, Smith J, Pirmohamed M, Park KB (2006) Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxic-ity. Gastroenterology (In press)

    Google Scholar 

  23. http://www.fda.gov/cber/gdlns/iche14qtc.htm.

  24. Pauli-Magnus C, Meier PJ (2005) Hepatocellular transporters and cholestasis. J Clin Gastroenterol 39(supp 2):S103–S110

    Article  PubMed  Google Scholar 

  25. Shah R (2006) Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7:889–908

    Article  CAS  PubMed  Google Scholar 

  26. Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645–656

    Article  CAS  PubMed  Google Scholar 

  27. Marshall A (1997) Getting the right drug into the right patient. Nat Biotechnol 15: 1249–1252.

    Article  CAS  PubMed  Google Scholar 

  28. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort prospective collaborative study (ISOCAT). Lancet 348:423–428.

    Article  CAS  PubMed  Google Scholar 

  29. Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ (2005) Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 96:595–8

    Article  PubMed  Google Scholar 

  30. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23–34

    Article  CAS  PubMed  Google Scholar 

  31. Reynolds KK, Bukavekas BL (2007) Current status of applied pharmacogenetics in clinical practice. Personalised Medicine 2007; 4:221–225

    Article  Google Scholar 

  32. Aithal GP, Day CP, Leathart JBS, Daly AK (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10:511–518

    Article  CAS  PubMed  Google Scholar 

  33. Long QT database initiative of the Working Group on Arrhythmias of the European Society of Cardiology. http://pc4.fsm.it:81/cardmoc/.

  34. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT (2000) Spectrum of mutations in long-QT syndrome genes KvLQT1, HERG, SCN5A, KCNE1 and KCNE2. Circulation 102:1178–1185

    CAS  PubMed  Google Scholar 

  35. Mohler PJ, Schott J-J, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V (2003) Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421:634–639

    Article  CAS  PubMed  Google Scholar 

  36. Priori SG, Napolitano C, Schwartz PJ (1999) Low penetrance in the long QT syndrome. Clinical impact. Circulation 99:529–533

    CAS  PubMed  Google Scholar 

  37. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between pre-clinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32–45

    Article  CAS  PubMed  Google Scholar 

  38. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Louis R, Cantilenar LR (2004) Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15:475–494

    Article  PubMed  Google Scholar 

  39. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175–187

    Article  CAS  PubMed  Google Scholar 

  40. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA (2000) A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 97:10613–10618

    Article  CAS  PubMed  Google Scholar 

  41. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM (2002) Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943–1948

    Article  CAS  PubMed  Google Scholar 

  42. Chevalier P, Rodriguez C, Bontemps L, Miquel M, Kirkorian G, Rousson R, Potet F, Schott JJ, Baro I, Touboul P (2001) Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Res 50:386–398

    Article  CAS  PubMed  Google Scholar 

  43. Danoff TM, Campbell A, McCarthy LC, Lewis KF, Repasch MH, Saunders AM, Spurr NK, Purvis IJ, Roses AD, Xu CF (2004) A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 4:49–53

    Article  CAS  PubMed  Google Scholar 

  44. Xu C-F, Lewis KF, Yeo AJ, McCarthy LC, Maguire MF, Anwar Z, Danoff TM, Roses AD, Purvis IJ (2004) Identification of a pharmacogenetic effect by linkage disequilibrium mapping. Pharmacogenomics J 4:374–378

    Article  CAS  PubMed  Google Scholar 

  45. Sun Z, Milos PM, Thompson JF, Lloyd DB, Mank-Seymour A, Richmond J, Cordes JS, Zhou J (2004) Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes. J Mol Cell Cardiol 37:1031–9

    Article  CAS  PubMed  Google Scholar 

  46. Ford GA, Wood SM, Daly AK (2000) CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol 50:77–80.

    Article  CAS  PubMed  Google Scholar 

  47. Molokhia M, McKeigue P (2006) EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 7:633–639

    Article  CAS  PubMed  Google Scholar 

  48. www.eudravigilance.org/human/evGateway01.asp.

    Google Scholar 

  49. http://dilin.dcri.duke.edu/about/index.html.

  50. http://www.wtccc.org.uk/.

  51. Motulsky AG (1957) Drug reactions, enzymes and biochemicalgenetics. JAMA 165:835–837

    CAS  Google Scholar 

  52. http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm

  53. Zika E, Gurwitz D, Ibarreta D (2006) Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impact in the EU. Institute for Prospective Technological Studies.

    Google Scholar 

  54. Lennard L (1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43:329–339.

    Article  CAS  PubMed  Google Scholar 

  55. Wang L, Weinshilboum R (2006) Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25:1629–1638

    Article  CAS  PubMed  Google Scholar 

  56. McLeod HL, Krynetski EY, Relling MV, Evans WE (2000) Genetic polymorphism of thiopu-rine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14:567–572

    Article  CAS  PubMed  Google Scholar 

  57. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui C-H, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001–2008

    Article  CAS  PubMed  Google Scholar 

  58. Evans WE, Horner M, Chu YQ, Oellerich M (1991) Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase deficient child with acute lymphoblastic leukemia. J Pediatr 119:985–89

    Article  CAS  PubMed  Google Scholar 

  59. Schutz E, Gummert J, Mohr F, Oellerich M (1993) Azathiopurine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipients. Lancet 341:436

    Article  CAS  PubMed  Google Scholar 

  60. Lennard L, Welch JC, Lilleyman JS (1997) Thiopurine drugs in the treatment of childhood leukemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 44:455–61

    Article  CAS  PubMed  Google Scholar 

  61. Cunliffe RN, Scott BB (2002) Monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 16:647–662

    Article  CAS  PubMed  Google Scholar 

  62. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR (2004) Cost effectiveness of thiopurine methyl transferase genotype screening in patients about to commence azathio-prine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 20:593–599.

    Article  CAS  PubMed  Google Scholar 

  63. van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E, Ibarreta D (2006) Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7:783–92

    Article  PubMed  Google Scholar 

  64. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko R, Wang H, Blanchard RL (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226–1236

    CAS  PubMed  Google Scholar 

  65. Smith NF, Figg WD, Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20:163–75

    Article  CAS  PubMed  Google Scholar 

  66. Morgan MY, Rehef R, Shah RR, Oates NS, Smith RL, Sherlock S (1984) Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25:1057–1064

    Article  CAS  PubMed  Google Scholar 

  67. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokohama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxocity: a pharmacogenetic analysis. Cancer Res 60:6921–6926

    CAS  PubMed  Google Scholar 

  68. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121–1122.

    Article  CAS  PubMed  Google Scholar 

  69. Pirmohamed M, Lin K, Chadwick D, Park BK (2001) TNF-alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 56:890–6

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

I would like to thank Dr. Ruth March for her input into this chapter, and Dr. Simon Smith and Professor Ann Daly for their critical reviews and comments.

Author information

Authors and Affiliations

  1. Research and Development Genetics, AstraZeneca, Cheshire, UK

    Martin Armstrong PhD

Authors
  1. Martin Armstrong PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Johnson and Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ, USA

    Nadine Cohen

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Armstrong, M. (2008). The Genetics of Adverse Drug Reactions. In: Cohen, N. (eds) Pharmacogenomics and Personalized Medicine. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-439-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-439-1_7

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-04-6

  • Online ISBN: 978-1-59745-439-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation